Finance entity
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention FiscalAI, the most common co-covered peer. The tracked stories average 2 original sources each. Moleculin Biotech, Inc. appears in 1 tracked Finance story from August 17, 2026.
Last mentioned: 1h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention FiscalAI, the most common co-covered peer. The tracked stories average 2 original sources each. Moleculin Biotech, Inc. appears in 1 tracked Finance story from August 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 14 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Moleculin Biotech, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Moleculin Biotech, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
